Novel Long-acting Pharmacotherapy for Exudative Age Related Macular Degeneration

Author(s): Elad Moisseiev*, Anat Loewenstein

Journal Name: Current Pharmaceutical Design

Volume 24 , Issue 41 , 2018

Become EABM
Become Reviewer
Call for Editor


Exudative age-related macular degeneration (AMD) is a major indication for the administration of intravitreal injections of anti-VEGF agents, which have been established as a very effective pharmacotherapy for this disease. However, treatment with anti-VEGF agents requires several patient visits for monitoring and treatment. Strategies for achieving a longer duration of pharmacological action are currently being developed. These include the development of longer-acting drugs, and of novel technologies to increase the duration of action of administered agents. This manuscript will review the novel drugs and technologies currently being developed for achieving a longer-action pharmacotherapy for exudative AMD.

Keywords: Age related macular degeneration, long term, long acting, intravitreal therapy, anti-VEGF agents, pharmacotherapy.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 20 March, 2019
Page: [4860 - 4863]
Pages: 4
DOI: 10.2174/1381612825666190123165216
Price: $65

Article Metrics

PDF: 43